Success rate of radioiodine therapy in Graves' disease: The influence of thyrostatic medication

Citation
O. Sabri et al., Success rate of radioiodine therapy in Graves' disease: The influence of thyrostatic medication, J CLIN END, 84(4), 1999, pp. 1229-1233
Citations number
37
Categorie Soggetti
Endocrynology, Metabolism & Nutrition","Endocrinology, Nutrition & Metabolism
Journal title
JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM
ISSN journal
0021972X → ACNP
Volume
84
Issue
4
Year of publication
1999
Pages
1229 - 1233
Database
ISI
SICI code
0021-972X(199904)84:4<1229:SRORTI>2.0.ZU;2-5
Abstract
There is controversy whether simultaneous thyrostatic medication influences the outcome of radioiodine (I-131) therapy in Graves' disease by reducing the absorbed energy dose of I-131 when delivering a standard dose. We there fore sought to ascertain whether the outcome of ablative I-131 therapy is i n any way affected by simultaneous thyrostasis (carbimazole) by aiming for a constant absorbed dose of 200-250 Gy. We prospectively studied 207 patien ts with Graves' disease (106 with and 101 without simultaneous carbimazole at the time of I-131 therapy). All patients were reexamined 3, 6, and 12 mo nths after I-131 therapy. The 101 nonthyrostatic patients showed a highly s ig nificantly greater success rate (93%) than the 106 thyrostatic patients (49%). Stepwise logistic regression demonstrated that failure was related t o the administration of carbimazole during I-131 therapy (P < 0.00005) and the absorbed dose (P < 0.025), but was not related to free T-3, free T-4, T SH receptor antibodies, or thyroid volume. The success rate was 100% in 93 nonthyrostatic patients with absorbed doses of 200 Gy or more, but was only 12.5% (1 of 8) for absorbed doses less than 200 Gy. Correlation between su ccess and absorbed dose was significantly higher for nonthyrostatic than fo r thyrostatic patients (r = 0.93 vs, r = 0.24). Sixteen patients who discon tinued thyrostasis 1-3 days before I-131 therapy showed 94% successes. Simultaneous thyrostasis is the decisive factor against a successful I-131 therapy even if the significantly reduced I-131 uptake/half-life values und er thyrostasis are compensated with a higher delivered dose to ensure a com parable absorbed dose, possibly due to the additionally effective radioprot ective properties of carbimazole. Therefore, if clinically feasible, we rec ommend discontinuing thyrostasis at least 1 day before beginning I-131 ther apy, because even in hyperthyroid nonthyrostatic patients the success rate was 100%.